KINDERHOOK, N.Y.--(BUSINESS WIRE)--June 21, 2006--American Bio Medica Corporation (NASDAQ: ABMC - News) today announced that the US Food and Drug Administration (FDA) has granted the Company 510(k) clearance on its Rapid One® lateral flow immunoassay test for the detection of Cocaine at 150 ng/ml. The Company had previously received clearance to detect Cocaine at 300 ng/ml. This new clearance allows the Company to provide its customers with a more sensitive point of collection test for Cocaine. The Company plans to offer its customers the option of purchasing either detection level for Cocaine.
